Nutriband sells 90% stake in Pocono Pharma for $5M to EarthVision Bio; retains 10%

NutriBand Inc.

Agreement to sell 90% interest in subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.
Nutriband shareholders will retain 10% stake in EarthVision Bio post-acquisition; closing expected Dec 31, 2025.
Proceeds will fund continued development of AVERSA Fentanyl, an abuse-deterrent opioid patch.
AVERSA Fentanyl has potential annual US sales estimate of $80M to $200M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.